• WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS
  • WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS
All/Company News/Scientific News/

Very soon – we are moving to Berlin’s TechnoCampus

10. Februar 2023

The keys for our new Berlin facilities at the TechnoCampus will be handed over next week and the excitement couldn’t be greater!   On March 1, the time has finally come and we will be able to welcome our business partners, healthy volunteers and patients at the new location!   The date for our grand… read more

CRS Clinical Research Services Berlin zieht um.

3. Februar 2023

CRS Clinical Research Services Berlin wird umziehen: von der Sellerstrasse 31 in Wedding in den modernen TechnoCampus am Berliner Siemensdamm. Wir sind glücklich darüber, unsere klinische Forschung dann in neuen, in jeder Hinsicht auf dem neuesten Stand und ganz nach unserem Bedarf ausgestatteten Räumen fortsetzen und robust für die Zukunft ausbauen zu können. In den… read more

First patient has been enrolled in a Phase 1a/b study with Atrogi’s drug candidate ATR-258.

1. Februar 2023

Our partner Atrogi announces first patient treated with its ATR-258 ß\2\ adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes – a milestone! For more information, click here.     read more

New Whitepaper: New strategies to improve clinical outcomes for diabetic kidney disease

10. Oktober 2022

Diabetes is a significant challenge for the global healthcare system: The International Diabetes Federation (IDF) estimates that healthcare expenditures already amount to USD 966 billion. In the coming years, the number of diabetics is expected to continue to increase significantly, and by 2045 it is estimated that 783 million people worldwide be living with the… read more

Herzinsuffizienz und Diabetes

15. August 2022

Um auf die Häufigkeit und das zuweilen tödliche Zusammenspiel dieser Erkrankungen vermehrt aufmerksam zu machen, haben die Deutsche Diabetes Gesellschaft (DDG) und die Deutsche Gesellschaft für Kardiologie (DGK) ein erstes gemeinsames Positionspapier herausgegeben. Unser Geschäftsführer und Chief Medical Officer, Prof. Dr. Thomas Forst, war an dessen Ausarbeitung beteiligt Wir freuen uns, Ihnen den Link zur… read more

100 Jahre Insulin

21. Juli 2021

2021 jährt sich zum hundertsten Mal ein zentrales Ereignis der Medizingeschichte: Die Isolierung von Insulin. Aus diesem Grund möchten wir Sie recht herzlich zum digitalen Event „100 Jahre Insulin“ einladen. Prof. Dr. Thomas Forst (Geschäftsführer & Chief Medical Officer bei CRS), wird mit seinem Vortrag „Ausblick: Grenzen der subkutanen Insulintherapie – wohin geht der Weg?“ zum… read more

Bayer AG and CRS Management GmbH extend strategic partnership

5. Mai 2021

We are proud that the strategic partnership between Bayer AG and CRS Clinical Research Services Management GmbH, which has existed since 2013, has now been extended ahead of schedule, and we are pleased that we may continue to support Bayer AG as a reliable partner in its early clinical development. Bayer AG and CRS look… read more

emovis and CRS

31. März 2021

We are proud to join forces with emovis GmbH in the development of COVID-19 treatments by offering combined clinical trials with healthy volunteers and SARS-CoV-2 patients. For more, see link below. https://www.emovis.de/en/services/covid-trial-unit/ read more

QUICK LINKS
  • WE ARE
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • MANAGEMENT
  • EARLY PHASE
    • First-in-human
    • Cardiac safety
    • Infusion & injection
    • Inhalation
    • Pharmacology
    • Interaction
    • Consultancy
    • Medical Writing
    • Data Management
.
  • PATIENT TRIALS
    • Cardiometabolics
    • Dermatology
    • Women‘s Health
    • Hemostaseology
    • Hepatology
    • Pulmology
    • Renal Impairment
    • Vaccines
    • Your individual request
  • SCIENCE
  • WORK WITH US
EXPERTISE
  • Consultancy
  • Medical Writing
  • Early Phase
FACILITIES
  • Berlin
  • Kiel
  • Mannheim
  • Wuppertal
FÜR PROBANDEN
  • ÜBER STUDIEN
  • AN STUDIEN TEILNEHMEN
  • www.probandeninfo.de
LEGAL
  • PRIVACY
  • IMPRINT
  • DISCLAIMER
  • —
  • Career
    • CURRENT JOB
    • OPPORTUNITIES
Copyright © 2023 CRS. Experts. Early Phase. All rights reserved.